2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Genomic Instability and Mutations
Genomic instability and mutations are central to cancer development and progression, as they contribute to the transformation of normal cells into malignant ones. Genomic instability refers to the increased rate of mutations within the DNA of a cell, leading to abnormal growth patterns. This instability can arise from various factors, including exposure to carcinogens, inherited genetic defects, or errors during cell division. Mutations in key genes, such as tumor suppressors and oncogenes, can drive the uncontrolled proliferation of cancer cells. Understanding the molecular mechanisms behind genomic instability is crucial for developing targeted therapies that address the root causes of cancer. Advances in genomic sequencing have enabled researchers to identify specific mutations that may be driving individual cancers, allowing for more personalized and effective treatments. By targeting these mutations, therapies can be designed to selectively kill cancer cells while sparing healthy tissue, improving both the efficacy and safety of treatment options.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China